

ECCO'24

Pfizer-sponsored medical education events.

## How did we do?

Thank you for visiting the XELJANZ® (tofacitinib citrate) booth today. We would be grateful for your feedback. This survey should take **no longer than 2 minutes** to complete.

### Your details

#### 1. Please indicate your profession:

- Physician (academic)  Physician (community)  Industry  Other

### Booth experience

#### 2. How would you rate your overall experience on the XELJANZ booth so far? (1 = poor; 10 = excellent)

1 2 3 4 5 6 7 8 9 10

### Pfizer-sponsored sessions

#### 3. Have you attended any of the Pfizer-sponsored sessions?

- Meet the Expert LIVE with Dr Gros  
(Thursday 22 February 14:00–14:30 CET and/or Friday 23 February 10:30–11:00 CET)
- Satellite symposium 'Patient journeys: a discussion of advanced therapy in UC'  
(Thursday 22 February, 19:00–20:00 CET)



#### 4. If so, to what extent do you feel the patient case studies improved your understanding of JAK inhibitor data?

0 1 2 3 4 5

Did not improve my understanding

My understanding was greatly improved

#### 5. To what extent do you feel the overall content improved your understanding of the suitability of JAK inhibitors for your patients?

0 1 2 3 4 5

Did not improve my understanding

My understanding was greatly improved

### General

#### 6. How interested would you be in attending future Pfizer medical education programmes? (1 = not at all interested; 10 = very interested)

1 2 3 4 5 6 7 8 9 10

Thank you for completing this evaluation survey – your feedback is greatly appreciated.

UC, ulcerative colitis.

This programme is not affiliated with ECCO. This programme is sponsored by Pfizer Inc. Pfizer Inc. is responsible for the costs incurred by inviting the faculty members to the meeting, along with purchasing the booth and symposium session. This programme is for healthcare professionals only.

PP-XEL-GLB-1793. February 2024. www.pfizer.com.  
©2024 Pfizer Inc. All rights reserved.



ECCO'24

Pfizer-sponsored medical education events.

## How did we do?

Thank you for visiting the XELJANZ® (tofacitinib citrate) booth today. We would be grateful for your feedback. This survey should take **no longer than 2 minutes** to complete.

### Your details

#### 1. Please indicate your profession:

- Physician (academic)    Physician (community)    Industry    Other

### Booth experience

#### 2. How would you rate your overall experience on the XELJANZ booth so far? (1 = poor; 10 = excellent)

1 2 3 4 5 6 7 8 9 10

### Pfizer-sponsored sessions

#### 3. Have you attended any of the Pfizer-sponsored sessions?

- Meet the Expert LIVE with Dr Gros  
(Thursday 22 February 14:00–14:30 CET and/or Friday 23 February 10:30–11:00 CET)
- Satellite symposium 'Patient journeys: a discussion of advanced therapy in UC'  
(Thursday 22 February, 19:00–20:00 CET)



#### 4. If so, to what extent do you feel the patient case studies improved your understanding of JAK inhibitor data?

0 1 2 3 4 5

Did not improve my understanding

My understanding was greatly improved

#### 5. To what extent do you feel the overall content improved your understanding of the suitability of JAK inhibitors for your patients?

0 1 2 3 4 5

Did not improve my understanding

My understanding was greatly improved

### General

#### 6. How interested would you be in attending future Pfizer medical education programmes? (1 = not at all interested; 10 = very interested)

1 2 3 4 5 6 7 8 9 10

Thank you for completing this evaluation survey – your feedback is greatly appreciated.

UC, ulcerative colitis.

This programme is not affiliated with ECCO. This programme is sponsored by Pfizer Inc. Pfizer Inc. is responsible for the costs incurred by inviting the faculty members to the meeting, along with purchasing the booth and symposium session. This programme is for healthcare professionals only.

PP-XEL-GLB-1793. February 2024. www.pfizer.com.  
©2024 Pfizer Inc. All rights reserved.

